Pfizer Q4 revenues down 9%
On average, 11 analysts polled by Thomson Reuters expected the company to report profit per share of $0.57, for the quarter.
Analysts' estimates typically exclude special items.
Adjusted income declined 17 percent year over year to $3.11 billion.
Fourth-quarter revenues were $12.7 billion, a decline of 9% year on year, reflecting an operational decline of 8%.
Analysts expected revenue of $12.61 billion for the quarter.
Biopharma revenues were $10.5 billion, up 9% operationally.
Fourth quarter Upjohn revenues were $2.2 billion, down 32% operationally, primarily driven by the expected significant volume declines for Lyrica in the U.S.
Excluding the unfavorable impact of Lyrica in the U.S. and other recent product losses of exclusivity, fourth-quarter revenues for Upjohn declined 6% operationally.
For fiscal 2020, Pfizer projects adjusted earnings per share in a range of $2.82 to $2.92; and revenues in a range of $48.5 billion to $50.5 billion.
Analysts polled by Thomson Reuters expect the company to report profit per share of $2.90 on revenue of $49.52 billion.
For New Pfizer, adjusted earnings per share is anticipated to be in a range of $2.25 to $2.35; and revenues are expected to be in a range of $40.7 billion to $42.3 billion.
During 2019, Pfizer returned $16.9 billion directly to shareholders.
As of January 28, 2020, Pfizer's remaining share repurchase authorization was $5.3 billion.
No share repurchases are currently planned in 2020. ■